Health ConditionsPerimenopause is defined as a period encompassing physiologic changes that result in the onset of menstrual irregularities and other symptoms, until a woman reaches menopause. According to the Stages of Reproductive Aging Workshop (STRAW), perimenopause commences with persistent differences in menstrual cycle length by more than 7 days. Menopause begins after 12 months of amenorrhea.
Traditionally, perimenopause includes an early and a late stage: the early stage is defined by occasional skipped cycles. The second stage is characterized by greater menstrual irregularity, with periods of amenorrhea lasting over 60 days and up to 12 months. Perimenopause can last for a variable amount of time, the median of which is four years.
The menopausal transition encompasses a median of four or more years, with median onset at age 47, progression to late menopausal transition at a median age of 49, and arrival at the final menstrual period at age 51–52. This progression varies according to the age at onset of the menopausal transition, with a cohort of earliest-onset symptoms translating to a longer median time of transition (8.6 years), as compared to a late-onset cohort demonstrating a shorter median time of transition (4.3 years).
No laboratory or imaging tests are needed to diagnose perimenopause after age 40 years, given the variability of follicle-stimulating hormone levels during this time and lack of meaningful cut-off values.
Fluctuating estrogen levels may cause heavy and irregular bleeding, vasomotor symptoms (i.e., hot flashes and night sweats), mood and memory changes, sleep disturbances, decreased libido, and genitourinary symptoms. These symptoms may precede the last menstrual period by up to 10 years.
Menopausal symptoms are highly prevalent; they are sufficiently bothersome to drive almost 90% of women to seek out their healthcare provider for advice on how to cope. The classic symptom of menopause is the hot flash, which is experienced by most women, and is moderately to severely problematic for about one-third of women.
This series of physical and psychological health problems is called perimenopausal syndrome and includes both short-term and long-term symptoms. Prominent symptoms include hot flashes, sweating, palpitations, paresthesia, irritability, and depression.
Psychogenic symptoms occur in up to 70% of women during perimenopause and menopause. Common manifestations include anger or irritability, anxiety or tension, and depression.
During perimenopause, menstrual periods may be late or early, longer than usual or shorter, and lighter than before, or heavier. They may disappear for several months, then reappear for several more.
Anovulation can cause irregular bleeding in perimenopause and is a risk factor for endometrial hyperplasia and cancer.
Perimenopause is characterized by the gradual loss of oocytes, altered responsiveness to gonadal steroid feedback, wide hormonal fluctuations, and irregular menstrual patterns. During perimenopause, ovulation occurs irregularly owing to fluctuations in levels of hypothalamic, pituitary, and ovarian hormones. Variability in the hormonal milieu within and across the stages of perimenopause is high.
Generally, the first apparent hormonal change of the perimenopause is a rising concentration of the pituitary gonadotrophin follicle-stimulating hormone (FSH). The rising FSH concentration is probably caused by an exponential decline of gonadotrophin-sensitive ovarian follicles as menopause approaches. Follicular development at this time has been demonstrated to be erratic, with consequent variability in estrogen levels and an increased percentage of anovulatory cycles. Thus, the pituitary gland is stimulated to produce more FSH in an effort to stimulate the resistant follicles.
Increases in FSH and decreases in inhibin B generally represent early changes, and are followed by decreases in both estradiol and inhibin A in the late stage of menopausal transition; however, significant variability is emphasized in all such reviews. Antimüllerian hormone correlates with follicle numbers and shows a large age-related decrease to reach undetectable levels at menopause.
Menopause is associated with significant hormonal changes, primarily a decrease in estrogen, androgen, and progesterone levels.
Although primarily viewed as a reproductive transition, the symptoms of perimenopause are largely neurological in nature. Neurological symptoms that emerge during perimenopause are indicative of disruption in multiple estrogen-regulated systems (including thermoregulation, sleep, circadian rhythms, and sensory processing) and affect multiple domains of cognitive function.
Estrogen is a master regulator that functions through a network of estrogen receptors to ensure that the brain effectively responds at rapid, intermediate, and long timescales to regulate energy metabolism in the brain. The estrogen receptor network becomes uncoupled from the bioenergetic system during the perimenopausal transition and, as a corollary, a hypometabolic state associated with neurological changes may emerge.
Cognitive problems are common during perimenopause and have a significant impact on a substantial proportion of women. Evidence continues to indicate that verbal learning and verbal memory are the cognitive functions that are most negatively affected during perimenopause, and new research suggests that perimenopause may also be associated with deficits in processing speed, attention, and working memory.
Estrogen also modulates serotonin and noradrenaline transmission, which supports mood stability. Perimenopausal women demonstrate a higher risk of depressive symptoms and greater symptom severity compared with premenopausal women. Vasomotor symptoms and additional factors that remain incompletely defined may contribute to this increased risk of depression during perimenopause and menopause.
Imaging studies suggest that estrogen deficiency is associated with large-scale negative changes in brain structure and activity. In comparison to age-matched males, females undergoing menopause showed significantly decreased gray matter volume in several cortical and subcortical regions.
The decline of estrogen levels is associated with a variety of devastating problems, majorly bone mass decrease, which causes osteopenia and osteoporosis. It has been well established that estrogens maintain bone mineral density (BMD) and reduce fracture risk at all sites.
Over the course of 24 months in one perimenopausal cohort study, mean bone mineral density decreased by −4.26%. In the same time period, the proportion of ovulatory cycles declined from 67% to 33%. The decrease in the ovulatory rate significantly correlated with enhanced BMD loss. The PeKnO study confirms a marked decline of the ovulatory rate during perimenopause, which is associated with an increased bone density loss while estrogen levels are still adequate. This finding indicates that bone loss during perimenopause is not solely attributable to estrogen deficiency but also to the progesterone-mediated effects of anovulation.
The essential cause of menopause is ovarian failure, which can cause decline in sex hormones (especially estrogen) that can increase the risk of metabolic diseases, such as cardiovascular disease and osteoporosis.
During perimenopause, estrogen helps regulate insulin production, glucose metabolism, and fat distribution. However, as levels become unstable in this phase, women may experience increased insulin resistance, shifts in fat storage, and a greater risk of metabolic disorders such as diabetes.
Estrogen and bone density of perimenopausal and postmenopausal women showed a downward trend with age, while total cholesterol and LDL levels increased.
Acute vasomotor, urogenital, and psychological symptoms characterize the perimenopause, as well as chronic reproductive, cardiovascular, neurological, skeletal, dermatologic, immune, and digestive changes of the postmenopause. The genitourinary tract, richly supplied with estrogen receptors, is particularly sensitive to hormonal fluctuation. Physical examination findings may reflect systemic effects of estrogen decline. Blood pressure may increase as a result of arterial vasoconstriction.
Multiple biological and social factors—including genetics, race, ethnicity, smoking history, stress, diet, exercise, and environment—contribute to the age of onset of menopause (median age = 51).
The Study of Women's Health Across the Nation (SWAN) has shown that Black and Latina women enter menopause earlier and have more severe vasomotor symptoms than white women. In the study, white women experienced vasomotor symptoms for around 6.5 years, Latina women 8.9 years, and Black women approximately 10 years.
SWAN has demonstrated that transit time to menopause can be impacted by other factors; for instance, African American women had a longer duration than white women, and greater body mass index was associated with a later onset of the menopausal transition.
Robust evidence indicates that overweight/obesity (BMI ≥25 kg/m²) and cigarette smoking were associated with the frequency and severity of vasomotor symptoms (VMS), in a dose-dependent manner. The chemicals in cigarette smoke affect reproductive function and alter hormone levels and their ratios — for example, producing higher androstenedione levels, a higher total androgen-to-total estrogen ratio, and lower progesterone levels, which have been associated with hot flushes.
Smokers who quit at fewer than 40 years of age were at similar levels of VMS risk as never-smokers.
Never-smokers who were obese had a 1.5-fold higher risk of often/severe vasomotor symptoms compared with never-smokers of normal weight. Smoking strengthened the association because the risk of often/severe vasomotor symptoms was much greater among smokers who were obese (relative risk ratio, 3.02).
Regardless of menopause, women gain an average of 10 kg between the ages of 40 and 60.
Major depression was observed in 3% of women at the SWAN baseline assessment. The risk for new onset of major depression increased as women became perimenopausal (OR = 2.27) and postmenopausal (OR = 3.57). Factors associated with major depression included stressful life events, history of an anxiety disorder, and psychotropic medication use—all of which approximately doubled the odds.
Perimenopause can occur earlier than the average age as a result of lifestyle factors like smoking. It can also be accelerated by medical treatments like chemotherapy or having a hysterectomy.
Lipid levels and urinary tract infections were risk factors for hypertension and perimenopausal syndrome, in addition to the presence of breast nodules, intake of snacks at night, high-salt diets, red meat, and sugar-sweetened beverages, and a history of smoking and drinking.
Osteoporosis is one of the most common metabolic bone diseases, with prominent loss of bone mass occurring in more than half of the women around age 50. Adequate calcium intake is therefore of primary concern during the perimenopausal transition. Postmenopausal women exhibit heightened susceptibility to deficiencies in calcium, vitamin D, magnesium, iron, and antioxidant micronutrients — deficiencies exacerbated by diminished dietary intake, impaired absorption, and sedentary lifestyles.
It is necessary to introduce lifestyle changes during this period to reduce the risk of fractures caused by osteoporosis, which include maintaining or achieving a healthy nutritional status and balanced nutrition focusing on adequate intake of vitamin D and calcium, regular exercise, smoking cessation, and stopping alcohol drinking.
Evidence characterization: The relationship between calcium intake and bone health in perimenopausal women is well-established and supported by multiple reviews and guidelines. However, evidence on whether supplemental calcium provides additional benefit beyond dietary calcium in peri- (as distinct from post-) menopausal women remains less definitive.
Vitamin D is essential for intestinal calcium absorption and is closely co-studied with calcium in the context of perimenopausal bone health. Key preventive nutrients in menopause include vitamin D, calcium, vitamin C, B vitamins, and protein intake.
Evidence characterization: Evidence for vitamin D as a nutritional support for skeletal health during the perimenopausal transition is robust in mechanistic and epidemiological terms, and vitamin D deficiency is widely reported in this population. Evidence specifically isolating perimenopause as a distinct population from postmenopause is more limited; most RCTs combine both groups.
Main elements of lifestyle changes for managing blood pressure include weight control, reducing alcohol and salt consumption, and increasing calcium, potassium, and magnesium intake. Magnesium acts synergistically with calcium and vitamin D in bone metabolism and also participates in neuromuscular and stress-related pathways relevant to perimenopausal symptoms including sleep disturbance and mood changes.
Evidence characterization: Magnesium's role in bone health is supported by mechanistic evidence. Evidence specific to perimenopausal symptom management is preliminary and largely based on small clinical studies and general nutrition research rather than large perimenopause-specific RCTs.
Omega-3 fatty acids (primarily EPA and DHA from marine sources) are studied in relation to cardiovascular risk, mood, and inflammation during perimenopause. Estrogen plays a protective role in cardiovascular health, and its decline can increase the risk of heart disease. A diet rich in heart-healthy fats, fiber, and antioxidants supports cardiovascular health by reducing cholesterol levels and oxidative stress.
Evidence characterization: Omega-3 (EPA/DHA) at 1–2 g/day may support cardiometabolic health but is not effective for hot flashes, as demonstrated in a large randomized trial. Evidence for omega-3s in mood support during perimenopause is preliminary.
B vitamins (particularly B6, B12, and folate) are discussed in the context of perimenopausal mood changes and cognitive function, given their roles in neurotransmitter synthesis and one-carbon metabolism. Nutrients like omega-3 fatty acids, magnesium, and B vitamins can support brain function, reduce stress, and promote emotional well-being. Including omega-3-rich foods, magnesium, and B vitamins may support brain health and alleviate anxiety and depression.
Evidence characterization: Evidence supporting B vitamin supplementation specifically for perimenopausal mood or cognitive symptoms is currently limited and largely extrapolated from general psychiatric nutrition research. Perimenopause-specific RCTs are lacking.
Phytoestrogens represent a diverse group of naturally derived non-steroidal plant compounds. Characterized by multiple hydroxyl-substituted aromatic rings, these molecules share a structural resemblance to endogenous estrogens, allowing them to interact with estrogen receptors and elicit estrogen-like or antagonistic biological responses. The major categories of phytoestrogens include isoflavones, lignans, coumestans, and resveratrol-like compounds. Isoflavones are predominantly found in leguminous plants, such as soybeans, chickpeas, and red clover. Lignans are abundant in flaxseeds, sesame seeds, whole grains, and certain vegetables.
Phytoestrogens are substances from plants that have chemical structures similar to those of the female hormone estrogen.
Traditional use: Dietary soy consumption has been a staple of East Asian cuisine for millennia, with populations in China, Japan, and Korea consuming significant quantities of soy-based foods (tofu, miso, tempeh, edamame) as part of their traditional diet. In these cultures, soy was consumed as a food rather than a medicinal supplement. Western interest in soy isoflavones as a functional agent for menopausal symptoms arose largely through epidemiological observations that women in Japan reported lower rates of hot flashes, though the interpretation of this finding remains contested in the literature.
Scientific evidence: Studies that tested isoflavones from soy or red clover for their ability to relieve menopause symptoms have had inconsistent results.
A 2025 systematic review and meta-analysis (PMC, PeerJ) specifically examined soy isoflavones in perimenopausal women. Soy isoflavones showed significant effects on headache, psychosocial symptoms, palpitation, and depression, but no significant treatment effect on paresthesia symptoms, fatigue symptoms, physical symptoms, hot flushes, excessive sweating, insomnia, and vasomotor symptoms was observed. However, these results should be interpreted with caution owing to the small sample size. More trials should be conducted in the future to validate the findings.
Phytoestrogen extracts, including soy foods and red clover, appear to have at best only minimal effect on menopausal symptoms but may have positive health effects on plasma lipid concentrations and may reduce heart disease risk.
Regarding safety: Although information on adverse effects is limited, soy extracts appear to be generally safe when taken for short periods of time. However, long-term use of soy extracts (which contain phytoestrogens) has been associated with thickening of the lining of the uterus. Current evidence indicates that it is safe for women who have had breast cancer or who are at risk for breast cancer to eat soy foods. However, it is uncertain whether soy isoflavone supplements are safe for these women.
Evidence characterization: Overall evidence is mixed. Dietary soy foods are well-tolerated and may offer modest cardiovascular benefit. Evidence for symptom reduction with soy isoflavone supplements specifically in perimenopause is preliminary, with inconsistent results across trials; most reviews note high heterogeneity of study designs, doses, and outcome measures.
Traditional use: Red clover has a long history in European and North American herbal traditions, used topically and internally for skin conditions, respiratory complaints, and as a blood-purifying tonic. Its use specifically for menopausal symptoms is a more recent development, driven by the identification of its high isoflavone content (formononetin, biochanin A, daidzein, and genistein).
Scientific evidence: Studies on the effects of red clover on menopause symptoms, such as hot flashes, and on blood levels of cholesterol and other lipids have had inconsistent results. A 2016 systematic review and meta-analysis found that red clover significantly improved vaginal dryness and vaginal atrophy, but showed less therapeutic effect on psychology status, sexual problems, and sleeping disorders. The review concluded that red clover consumption may decrease frequency of hot flashes, especially in women with severe hot flashes (5 or more per day).
Evidence characterization: Evidence is mixed and of variable quality. Some benefit for vasomotor symptoms is suggested, particularly in women with higher baseline frequency; effect sizes are modest. Long-term safety data are limited. The NCCIH notes overall inconsistent results across trials.
Traditional use: Black cohosh is an herb native to North America. The roots and rhizomes (underground stems) of the plant are used in dietary supplements. It was used extensively by several Native American peoples for gynecological conditions, including menstrual irregularities and childbirth support. It was later adopted into eclectic medicine in the 19th century and subsequently became one of the most widely studied herbs for menopausal symptoms in Western phytotherapy.
Scientific evidence: Research suggests that certain black cohosh extracts and some combination products containing black cohosh may reduce some menopause symptoms. Most of the research has been on the single extract Remifemin. Research on other black cohosh products has had inconsistent results. Guidelines released in 2015 indicate that there is a lack of consistent evidence for any benefit from black cohosh for menopause symptoms.
Studies that tested black cohosh for menopause symptoms have had inconsistent results. A 2012 research review concluded that there's not enough evidence to support its use for menopause symptoms.
An RCT involving 88 perimenopausal and postmenopausal women assigned to receive black cohosh (128 mg/day of 75% ethanolic extract), red clover, multibotanical preparations, or placebo found that there were no statistically significant differences between the black cohosh and red clover groups compared to placebo, with one exception: the black cohosh group showed worse symptom intensity at 6 and 9 months. After 3, 6, 9, and 12 months of supplementation or placebo, the number of vasomotor symptoms declined significantly in all groups.
Regarding mechanism: Black cohosh does not directly bind to estrogen receptors, suggesting a mechanism independent of classical estrogen receptor pathways.
Preliminary laboratory research suggests that black cohosh might affect statin medicines used to reduce blood cholesterol levels. It is not clear if black cohosh is safe for women who have had hormone-sensitive conditions such as breast cancer.
Evidence characterization: Black cohosh is one of the most extensively studied herbs in this context. Evidence is inconsistent: some trials show modest benefit for vasomotor symptoms, while others do not. Most high-quality guidelines characterize the overall evidence base as insufficient to support a positive recommendation.
Traditional use: Flaxseed (linseed) has been cultivated for thousands of years across Eurasia and the Mediterranean, primarily as a food and textile plant. Its seeds and oil have historically been used in folk medicine for their lubricating, anti-inflammatory, and laxative properties.
Scientific evidence: Studies of flaxseed products found them to be no more effective than a placebo in reducing hot flashes. Flaxseed is a rich source of the plant lignan secoisolariciresinol diglucoside (SDG), which is converted by gut microbiota to the enterolignans enterodiol and enterolactone. Trials combining black cohosh, soy isoflavones, and SDG lignans also yielded favorable outcomes.
Evidence characterization: Evidence for flaxseed in relieving perimenopausal vasomotor symptoms is currently negative based on controlled trials. Flaxseed's broader nutritional profile (fiber, alpha-linolenic acid, lignans) may contribute to cardiovascular and metabolic health, but perimenopause-specific benefits remain unproven.
Traditional use: Valerian is a plant whose root and rhizome are used medicinally. Its root has been used for the treatment of different diseases such as dizziness, neural pains, and anxiety. Because of its phytoestrogenic components, valerian is also recommended in traditional and herbal practice for the reduction of menopause symptoms, sleeplessness, and mental disorders. Valerian has deep roots in European folk medicine, being used since at least Greco-Roman antiquity as a sedative and nervine.
Scientific evidence: Evidence for valerian in perimenopausal and menopausal contexts is early-stage. There are some early signs that valerian root may help reduce hot flashes. One study of 68 women demonstrated that those who took valerian capsules three times a day for eight weeks experienced a reduced number of hot flashes. A 2018 randomized study in 60 menopausal women found that valerian decreased the frequency and severity of hot flashes. Evidence for sleep support is more consistent in general adult populations, though it is not menopause-specific.
Evidence characterization: Evidence is preliminary and based on small trials. Study quality is variable. Valerian cannot currently be recommended with confidence for perimenopausal vasomotor symptoms based on the available evidence.
Traditional use: Maca is a root vegetable native to the high-altitude Andes of Peru and Bolivia, where it has been cultivated for at least 2,000 years as a food staple. In traditional Andean medicine it was used to enhance energy, fertility, and stamina. Its use for perimenopausal and menopausal symptoms is a modern Western application based on bioactive compounds called macamides and glucosinolates, which are thought to act on the hypothalamic-pituitary axis rather than through direct estrogenic activity.
Scientific evidence: Only a handful of studies have evaluated maca for its effectiveness in treating symptoms of menopause. Some small studies have indicated that maca may be effective in treating mild depression and boosting libido in postmenopausal women. Although no significant side effects have been reported, the safety of this supplement has not been rigorously evaluated. A 2022 review of studies found that maca may have an effect on memory impairment, depression, and bone structure in menopausal women. However, more high-quality research is necessary to verify these findings.
Evidence characterization: Evidence is preliminary, based on small pilot studies and reviews of low-to-moderate quality. No large RCTs specific to perimenopause have been completed. Safety data are limited.
Traditional use: Ashwagandha is a foundational herb of Ayurvedic medicine, categorized as a rasayana (rejuvenating tonic) and adaptogen. It has been used for thousands of years in the Indian subcontinent for conditions including debility, fatigue, sexual dysfunction, and anxiety. Its application to perimenopausal symptoms is an extension of its general adaptogenic and stress-modulatory role.
Scientific evidence: A randomized, double-blind, placebo-controlled study included 60 women aged 45–55 years who received either ashwagandha root extract or a placebo for 56 days. The primary outcome was a change in the Menopause Rating Scale score. The conclusion was that ashwagandha root extract can be a potential herbal intervention for managing menopausal symptoms in healthy women. A separate RCT (PubMed, 2025) found that daily supplementation with ashwagandha extracts dose-dependently reduces menopausal symptoms, vascular dysfunction, bone turnover/resorption, and estrogen deficiency-related inflammation and oxidative stress in postmenopausal women. Ashwagandha is noted for a range of relevant properties, including anti-stress, anti-aging, immune support, anti-inflammatory, cognition enhancement, anxiety relief, adaptogenic properties, and sleep promotion.
Evidence characterization: Evidence is emerging and encouraging but currently limited by small sample sizes, short trial durations, and heterogeneous outcome measures. Larger, longer perimenopause-specific trials are needed before strong conclusions can be drawn.
Traditional use: Vitex has a history of use dating back to ancient Greece and Rome, where it was associated with female chastity and gynecological health. In European herbal tradition (and in the German Commission E monograph) it has been used for premenstrual syndrome, breast tenderness, and menstrual irregularities associated with corpus luteum insufficiency — conditions that are closely related to the hormonal fluctuations of early perimenopause.
Scientific evidence: Vitex has been widely used in traditional medicine, with preliminary studies indicating its effectiveness in alleviating menopausal symptoms. Its proposed mechanism involves dopaminergic activity that moderates prolactin secretion and an indirect influence on progesterone-to-estrogen ratios. However, large, well-designed RCTs specifically in perimenopausal women are lacking, and most supporting evidence comes from PMS-focused trials rather than perimenopausal cohorts.
Evidence characterization: Traditional use is well-documented in European phytotherapy monographs, particularly the German Commission E. Evidence specific to perimenopause is preliminary; most robust clinical data relate to premenstrual disorders rather than the perimenopausal transition per se.
Traditional use: Dong Quai is a herb that grows in the high altitude mountains of China, Japan, and Korea. It is one of the most widely used herbs in Traditional Chinese Medicine (TCM), where it is known as dang gui and has been prescribed for thousands of years primarily as a "blood tonic" for gynecological conditions including menstrual irregularities, dysmenorrhea, and menopausal complaints. It is rarely used alone in TCM, where it is typically combined in multi-herb formulas.
Scientific evidence: Dong Quai has been shown to affect estrogen levels in animals, but there is no evidence that the same effect occurs in humans. One clinical study of over 70 women showed that Dong Quai did not improve symptoms of hot flashes or vaginal dryness.
Evidence characterization: Current clinical evidence does not support the use of Dong Quai as a monotherapy for vasomotor perimenopausal symptoms. Its traditional use as part of compound formulas has not been rigorously tested in isolation.
Menopause's onset is linked to a heightened prevalence of obesity, metabolic syndrome, cardiovascular disease, and osteoporosis. Diet is particularly relevant during menopause given its impact on quality of life and longevity and its modifiability.
A 2024 cross-sectional study in Australian perimenopausal and menopausal women investigated adherence to a Mediterranean-style diet. Low consumption of sugar-sweetened beverages was inversely associated with joint and muscle complaints. Adherence to a Mediterranean-style diet was positively associated with the physical function subscale of health-related quality of life, and low intake of red and processed meat was positively associated with the general health subscale. Diet quality may be related to severity of menopausal symptoms and health-related quality of life in perimenopausal and menopausal women. However, exploration of these findings using longitudinal analyses and robust clinical trials are needed to better elucidate these findings.
A related prospective cohort study found that fruit-rich and Mediterranean-style dietary patterns were associated with the risk of night sweats and hot flushes in midlife women, underscoring that dietary pattern effects on vasomotor symptoms may be complex and are not uniformly protective.
A comprehensive 2023 review published in PMC (The Importance of Nutrition in Menopause and Perimenopause) summarizes dietary priorities for this life stage:
A 2025 systematic review of RCTs on lifestyle interventions in perimenopausal women concluded that no studies exclusively examined diet-based interventions. The findings suggest that both exercise and health education might offer benefits in managing perimenopausal symptoms.
Optimizing lifestyle factors during perimenopause — specifically, healthy weight and physical activity — and screening for cardiovascular risk factors are important priorities.
Exercise and dietary modifications need not be used in isolation but can be an adjunct treatment to existing hormonal therapies to further improve the overall response, health, and well-being of a woman suffering from perimenopausal symptoms.
Research has shown clear links between how much alcohol women consume and their risk of depression, both during and after the menopause transition. Alcohol reduction is included among the lifestyle modifications recommended in major perimenopausal lifestyle reviews.
Hormonal changes can lead to a slower metabolism, increased abdominal fat, and weight gain. A balanced diet can help maintain a healthy weight and prevent obesity-related complications. Perimenopausal syndrome shares common risk factors with hypertension during perimenopause, such as BMI and dyslipidaemia.
Current evidence on estrogen's metabolic influence provides clinicians with practical, evidence-based strategies for identifying at-risk women and implementing targeted interventions, including lifestyle modifications, phytoestrogen use, and hormone therapy. Perimenopause represents a pivotal opportunity to optimize long-term metabolic outcomes in women.
The increasing lifespan of women and their extended time spent in menopause pose significant challenges for health care systems, primarily due to the impacts of postmenopausal estrogen deficiency and aging on health. Menopause's onset is linked to a heightened prevalence of obesity, metabolic syndrome, cardiovascular disease, and osteoporosis.
Regarding Alzheimer's disease risk, emerging preclinical and epidemiological data suggest that the perimenopausal window may be a critical period of neurological vulnerability. Research supports the idea that perimenopause represents a critical window of emerging vulnerability to Alzheimer's-related brain changes where intervention may be beneficial. However, much of this evidence currently derives from animal models, and large prospective human studies remain ongoing.
The latest research suggests that initiating phytoestrogen supplementation during the early stages of menopause (such as the perimenopausal and early postmenopausal periods) may be more beneficial for cardiovascular health. Large, long-term trials are needed to confirm their safety and mechanisms.
5-HTP is a direct precursor to serotonin, with clinical relevance to perimenopausal mood disturbances, anxiety, sleep disruption, and vasomotor symptoms. Perimenopause-specific expert guidance (Revolution Health, citing clinical sources) includes 5-HTP as a serotonin-supporting supplement when hormonal shifts affect serotonin balance, triggering emotional turbulence.
8-Prenylnaringenin (8-PN), the principal phytoestrogen in hops (Humulus lupulus), is considered one of the most potent plant-derived estrogen receptor ligands known. Standardized hop extracts have been studied in RCTs for menopausal vasomotor symptoms, with a first prospective randomized double-blind placebo-controlled trial (Heyerick et al., 2006) showing reduction of menopausal discomfort.
ALA is the plant-based omega-3 fatty acid abundant in flaxseed, which is used in perimenopause for its phytoestrogenic lignan content as well as its anti-inflammatory fatty acid profile. Flaxseed ALA contributes to the overall perimenopausal benefit profile of flaxseed alongside its lignan content.
Ashwagandha (Withania somnifera) root extract has been directly studied in a published 8-week, randomized, double-blind, placebo-controlled trial (Gopal et al., 2021, Journal of Obstetrics and Gynaecology Research) in 100 perimenopausal women. The ashwagandha group showed significant improvement in climacteric symptoms, quality of life, and hormonal parameters.
Multiple 2025 randomized, double-blind, placebo-controlled trials have evaluated standardized A. racemosus (shatavari) root extract specifically for perimenopausal symptoms including vasomotor symptoms, menstrual irregularities, and hormonal biomarkers, consistently showing significant improvements over placebo. This represents the most clinically developed area of asparagus supplementation research.
Black cohosh (Actaea racemosa) is the most extensively studied botanical for perimenopausal symptoms. Multiple RCTs and reviews report reductions in hot flash frequency and improvements in overall menopausal symptom scores. It appears to act via serotonergic rather than estrogenic pathways. Evidence is mixed but a 2023 clinical trial found significant improvement versus placebo.
Calcium supplementation is officially recommended by the European Menopause and Andropause Society for perimenopausal women to protect bone mineral density as estrogen declines. Combined with vitamin D, it reduces risk of osteoporosis and fractures. Adequate calcium intake is a recognized clinical standard for perimenopausal bone health.
Chaste tree (Vitex agnus-castus) is the same herb as Vitex Agnus-Castus, extensively used and studied for perimenopausal hormonal balance. It modulates dopamine/prolactin pathways to support progesterone/estrogen regulation and has clinical RCT evidence for reducing perimenopausal symptoms including irregular cycles, mood changes, breast tenderness, and hot flashes.
Daidzein is an isoflavone phytoestrogen found in soybeans and red clover that binds ERβ with SERM-like activity. Clinical trials demonstrate that daidzein, especially in equol-producing individuals, reduces vasomotor symptoms including hot flashes and night sweats during the menopausal transition.
Small clinical studies and an observational study with a T. diffusa-containing formulation showed improvements in menopausal transition symptoms. MSKCC acknowledges damiana-containing formulas may improve menopausal symptoms. T. diffusa leaf extract is the only pharmaceutical therapy option in Germany for FSIAD, a condition overlapping with perimenopause.
DHA is a key long-chain omega-3 fatty acid with evidence for cognitive support, mood regulation, and anti-inflammatory activity during perimenopause. It is specifically noted in perimenopausal contexts for brain fog and mood, and is included in algae-based formulations recommended for perimenopausal women.
DHEA has been studied in perimenopausal women alongside postmenopausal populations. Intravaginal DHEA was found to be a safe and effective treatment for vulvovaginal atrophy and dyspareunia in peri- and postmenopausal women. A Cochrane review noted that DHEA may slightly improve sexual function in this population but with uncertain effects on quality of life.
DIM has been studied in perimenopausal and postmenopausal women for its ability to alter urinary estrogen metabolite profiles, specifically increasing the 2-OHE1:16α-OHE1 ratio. A UC Berkeley human clinical trial demonstrated this shift in estrogen metabolites in women with breast cancer history. DIM is used clinically to address estrogen-dominant perimenopausal symptoms.
EPA is an omega-3 fatty acid with specific evidence for reducing perimenopausal depression and hot flash frequency. EPA-dominant formulations demonstrate solid evidence for reducing depressive symptoms—a disproportionately common perimenopausal complaint. Combined EPA+DHA reduces hot flash frequency in clinical studies.
Evening primrose oil (EPO), rich in gamma-linolenic acid (GLA), has been investigated for reducing hot flash severity in perimenopausal women. A 2018 RCT found EPO reduced hot flash severity, though a 2021 study found no significant effect on frequency. It is widely used traditionally for menopausal symptom relief and is listed by NCCIH among studied botanicals.
Fenugreek's phytoestrogenic action is applicable to perimenopause, the transitional period of declining estrogen preceding full menopause. RCT evidence using standardized extracts in women experiencing menopausal symptoms supports benefit for vasomotor, urogenital, and mood-related symptoms that begin during perimenopause.
Flaxseed is the richest dietary source of lignans (secoisolariciresinol diglucoside, SDG), which are converted by gut microbiota to enterodiol and enterolactone—phytoestrogens that bind estrogen receptors. A 2024 single-blind RCT specifically in perimenopausal women found significant increases in lignan metabolites and improvements in perimenopausal symptoms.
GABA is the primary inhibitory neurotransmitter, with declining availability during perimenopause contributing to anxiety, insomnia, and mood instability. Revolution Health's evidence-based perimenopause guidance lists GABA supplements for mood stabilization. Progesterone's metabolite allopregnanolone is a potent GABA-A modulator, and its decline during perimenopause directly impairs GABAergic signaling.
Gamma oryzanol's evidence for menopausal symptom relief extends to perimenopausal women undergoing the menopausal transition. A 2023 RCT (NCT05922800) specifically enrolled women during the menopausal transition period alongside postmenopausal women. Its hypothalamic-pituitary modulating effects are relevant during the perimenopausal hormonal fluctuation phase.
Genistein is the most bioactive soy and red clover isoflavone, binding ERβ preferentially and acting as a SERM. Clinical evidence supports reduction of hot flashes, night sweats, and improved bone mineral density in menopausal women. It is the most studied individual soy isoflavone for menopausal symptoms.
Ginseng (Panax ginseng, Asian/Korean) has been evaluated in multiple RCTs for menopausal symptoms. A systematic review found ginseng may improve hot flashes and quality of life in menopausal women. It is particularly noted for psychological symptoms and sleep. However, evidence for vasomotor symptom reduction is limited.
Gamma-linolenic acid (GLA), an omega-6 fatty acid predominant in evening primrose oil and borage oil, has been studied as an active component for perimenopausal hot flash relief via prostaglandin pathway modulation. It is the key bioactive constituent underlying evening primrose oil's studied benefits during perimenopause.
HMRlignan's phytoestrogenic metabolite enterolactone modulates estrogen receptors ERα and ERβ, offering weak estrogenic support relevant to the hormonal fluctuations of perimenopause. The clinical study in postmenopausal women demonstrating hot flash reduction, combined with its established bioconversion to enterolactone, supports relevance to the broader perimenopausal transition. Evidence is preliminary and limited to one small industry-funded clinical study.
The phytoestrogen 8-prenylnaringenin in hops exerts estrogenic activity relevant to the perimenopausal transition. Clinical trials of standardized hop extracts have reported improvements in the broader Menopause Rating Scale (MRS) including physical, psychological, and urogenital symptom domains. Evidence is largely the same body of trials supporting hot flash reduction.
Perimenopause is associated with increased insulin resistance, dyslipidemia, and cardiometabolic risk; inositol has been clinically studied in peri- and postmenopausal women for these outcomes. A 6-month RCT in postmenopausal women with metabolic syndrome found myo-inositol supplementation improved fasting glucose, insulin sensitivity, and lipid profiles. Inositol also transduces TSH signaling, which becomes increasingly relevant as thyroid function changes around menopause.
Isoflavones are a class of phytoestrogens (including genistein, daidzein, formononetin, biochanin A) from soy and red clover with well-studied clinical evidence for perimenopausal and menopausal vasomotor symptoms, bone health, and mood. Meta-analyses confirm modest but statistically significant reductions in hot flash frequency and severity.
Three randomized controlled trials in perimenopausal and menopausal women have found kava extracts significantly reduce anxiety, depression, and irritability associated with the perimenopausal transition. One trial in 40 perimenopausal women found statistically significant improvement on anxiety scales; another found kava augmented the anxiolytic effect of hormone replacement therapy. Hot flash reduction was not a primary or consistent endpoint.
The same phytoestrogenic mechanisms and clinical evidence supporting licorice for menopausal hot flashes apply to the perimenopausal transition. Authoritative reviews list menopause and its peri-phase as key indications for glycyrrhizin-containing licorice. A double-blind RCT in menopausal women demonstrated clinically significant reduction in vasomotor symptoms.
Lignans act as phytoestrogens whose metabolites (enterolactone, enterodiol) structurally resemble estradiol, potentially moderating hormonal fluctuations during the perimenopausal transition. A 2025 review confirmed flaxseed lignans reduced perimenopausal symptoms. The phytoestrogenic action may help buffer against declining endogenous estrogen levels through partial agonist/antagonist activity at estrogen receptors.
Lily bulb polysaccharides and saponins have been studied in ovariectomized mouse models for menopausal symptoms, demonstrating effects on anxiety, depression, cognition, and endocrine markers via estrogen receptor β pathways. Preliminary clinical evidence supports lily-bulb-containing herbal formulas for alleviating climacteric syndrome. A PMC study (PMC6683782) specifically found total polysaccharides ameliorated menopause-like behavior in OVX mice.
Maca (Lepidium meyenii), traditionally used in the Peruvian Andes, has been studied in RCTs for perimenopausal and menopausal symptoms. RCT evidence shows modest reductions in vasomotor symptoms, anxiety, and depression. It is considered non-estrogenic, acting via hypothalamic-pituitary axis modulation.
Magnesium is commonly used for perimenopausal symptoms including sleep disturbance, mood instability, muscle relaxation, and general hormonal balance. Evidence indicates it improves sleep and well-being during the menopause transition. An active 2026 clinical trial (NCT07235878) is specifically investigating magnesium hydroxide supplementation on perimenopausal symptoms.
Melatonin levels decline during perimenopause, paralleling worsening sleep. A review found doses above 3 mg improved common menopausal symptoms including hot flashes, insomnia, mood changes, and sexual disorders. An RCT in perimenopausal women taking 3 mg nightly for 6 months showed improved sleep quality and tolerability.
Omega-3 fatty acids (EPA and DHA) have evidence for reducing hot flash frequency, improving mood, and supporting cognitive health during the menopausal transition. A 2020 study found omega-3 supplementation reduced hot flash frequency in menopausal women. EPA-dominant formulations have solid evidence for depressive symptoms, which are disproportionately common during perimenopause.
Passionflower (Passiflora incarnata) is used for perimenopausal sleep disturbances, anxiety, and mood symptoms. Clinical evidence supports its anxiolytic and sleep-promoting effects via GABA-A receptor modulation. Perimenopause expert guidance (Revolution Health) specifically lists passionflower alongside melatonin and valerian for perimenopausal sleep cycle disruption.
Phytoestrogens are plant-derived compounds (isoflavones, lignans, coumestans, prenylated flavonoids) that bind ERβ as weak SERMs. They are the most extensively studied class of natural compounds for perimenopausal vasomotor symptoms, bone health, and mood. Major dietary sources include soy, red clover, flaxseed, and hops.
The 2023 systematic review and meta-analysis (Wiley Phytotherapy Research) included perimenopausal women and found pomegranate significantly improved hot flash severity, menopausal symptom scores, and FSH levels across peri- and postmenopausal populations. Pomegranate seed oil phytoestrogens are the proposed active components.
During perimenopause, ovarian steroid output becomes erratic while adrenal pregnenolone-derived hormones gain importance. Pregnenolone's role as upstream precursor to progesterone, DHEA, and estrogens positions it as a potential therapeutic target. Its neurosteroid properties also address the mood, sleep, and cognitive changes characteristic of perimenopause.
Red clover (Trifolium pratense) contains isoflavones—formononetin, biochanin A, daidzein, and genistein—that act as phytoestrogens, binding estrogen receptors to produce weak estrogenic effects. A review of 4 RCTs showed one trial with significant hot flash reduction versus placebo. Doses of 40–80 mg isoflavones/day are commonly used.
Multiple clinical trials specifically enrolled perimenopausal women and tested ERr 731 (Rheum rhaponticum root extract), demonstrating significant reductions in climacteric complaints including vasomotor symptoms, anxiety, and sleep disturbances with 4 mg/day for 12 weeks.
Sage (Salvia officinalis) is used traditionally and in clinical practice for perimenopausal hot flashes and night sweats. A NIH/NCCIH-referenced RCT (n=30, sage plus alfalfa) showed significantly greater reduction in hot flash frequency at 12 weeks versus placebo. Sage can lessen hot flash intensity within weeks.
Secoisolariciresinol diglucoside (SDG) is the principal lignan in flaxseed, converted by gut microbiota to mammalian phytoestrogens enterodiol and enterolactone. A 2024 single-blind RCT in perimenopausal women found flaxseed/SDG supplementation significantly increased lignan metabolite levels and improved perimenopausal symptoms.
Soy isoflavone supplementation has been specifically studied in perimenopausal women for relief of vasomotor symptoms. A 2025 meta-analysis of RCTs in perimenopausal women found significant efficacy for hot flashes and overall menopausal symptom scores with soy isoflavones vs. placebo.
Soy isoflavones (genistein, daidzein, glycitein) are phytoestrogens that bind ERβ and exert mild estrogenic effects useful in perimenopause. A 2025 meta-analysis of 12 RCTs (533 participants) found statistically significant benefit for menopausal symptoms (Hedges' g = −0.25). Evidence supports reduction in hot flash frequency and potential bone benefit.
Soy isoflavones have been studied in perimenopausal women for relief of vasomotor and other transitional symptoms, with a 2025 PMC systematic review and meta-analysis specifically evaluating their effects in this population. Effects on hot flashes and depression symptoms have been documented in perimenopausal women. The phytoestrogenic activity of soy isoflavones is considered especially relevant during the perimenopausal transition when endogenous estrogen is fluctuating.
St. John's Wort (Hypericum perforatum) is well-established for mild to moderate depression and has specific evidence for perimenopausal mood-related symptoms. Combined with black cohosh, it significantly improved mood swings in perimenopausal women in clinical trials. The NCCIH and NCCIH-referenced sources cite it as one of the studied supplements for menopause.
Valerian root is a traditional medicinal plant with established use for anxiety and insomnia, conditions highly prevalent during perimenopause. NCCIH acknowledges its study for menopausal symptoms. GoodRx and clinical perimenopause guidance list valerian for sleep cycle disruption and anxiety in perimenopausal women.
Vitamin D is critical for bone health during perimenopause, as declining estrogen accelerates bone turnover. It is officially recommended by the European Menopause and Andropause Society, works synergistically with calcium to reduce osteoporosis risk, and is associated with improved mood, reduced inflammation, and support for vasomotor and immune function during the menopausal transition.
Vitamin D3 (cholecalciferol) is the preferred, most bioavailable form of vitamin D for supplementation and is specifically used in perimenopausal care for bone health, mood, immune function, and overall hormone regulation during the menopausal transition. European Menopause Society guidelines support its use.
Vitex agnus-castus (chaste tree berry) has been used since ancient Greece for female hormonal regulation. Clinical studies and a 2025 PubMed review confirm it modulates dopaminergic and serotonergic pathways to reduce prolactin and support progesterone/estrogen balance. It shows benefit for perimenopausal symptoms including irregular cycles, mood changes, and breast tenderness.
Alfalfa's phytoestrogen content has led to its traditional and modern herbal use for perimenopausal hormonal fluctuations, including mood swings, hot flashes, and cycle irregularities. Scientific evidence specific to perimenopause and alfalfa alone is lacking; its use is extrapolated from phytoestrogen pharmacology.
Epimedium has a classical TCM use for menopausal syndrome, including perimenopausal symptoms related to kidney deficiency and declining reproductive hormones. Its phytoestrogenic activity provides biological plausibility. The 2022 review confirms its broad clinical use in China for aging and hormone-related diseases including menopausal syndrome.
Dong quai (Angelica sinensis) has been used for over two millennia in Traditional Chinese Medicine (TCM) for female hormonal complaints including menstrual irregularity, menopausal symptoms, and insomnia. Scientific RCT evidence when used alone shows no significant benefit over placebo for hot flashes, but combination TCM formulas show positive results.
Dong quai root (Angelica sinensis root) is the specific plant part used in Traditional Chinese Medicine formulations for perimenopausal hormonal support, menstrual regulation, and symptom relief. Combination studies with other botanicals show reduction in hot flashes and night sweats during the menopausal transition.
Wild yam (Dioscorea villosa) has a long traditional use in North American herbal medicine for female hormonal complaints including perimenopausal symptoms. It contains diosgenin, a steroid sapogenin used industrially to synthesize progesterone, but the body cannot perform this conversion. Animal and human studies suggest it may protect against osteoporosis.
The same traditional framework and in vitro estrogenic data that apply to menopause extend to perimenopause. Traditional European and Persian herbal practice includes yarrow as a female hormonal regulator, but dedicated perimenopausal clinical studies do not exist.
Go back